

# HCVPOCT

National Australian Hepatitis C Point-of-Care Testing Program

## Evaluation of operator training and quality management for point-of-care testing for hepatitis C infection.

Sub study funded by CRE Rapid  
**Corey Markus**

Research Officer

International Centre for Point-of-Care Testing

Flinders University



**2021: Flinders University International Centre for Point-of-Care Testing Staff**




# Demonstration Study


## The National Australian HCV Point-of-Care Testing Program

### Primary Objective

To evaluate the proportion of HCV RNA positive participants who initiate HCV treatment within 12 weeks of finger-stick point-of-care HCV RNA testing.




**58 Sites**



Rapid anti-HCV antibody test with reflex HCV RNA test with diagnosis (Health Care Workers)


# GeneXpert HCV VL Fingerstick Assay

- *In vitro* reverse transcription polymerase chain reaction (RT-PCR) assay for the detection and quantification of HCV RNA
- Able to detect HCV infections in capillary blood using Minivette® in 58 minutes
- Conditions of TGA certification:
  - a. NATA medical testing laboratories with HCV EQA participation; OR
  - b. organisations that:
    - i. **train health professionals** to perform and **supervise HCV testing**; and
    - ii. have established referral and testing pathways with NATA accredited lab; and
    - iii. **Participate in HCV External Quality Assurance (EQA)**



|           | IVD Classification | Risk   | Example  |
|-----------|--------------------|--|--|
| Low Risk  | Class I            | No public health or low personal risk        | Glucose Meter  |
|           | Class II           | No public health or moderate personal risk   | Pregnancy/Fertility self-test                              |
|           | Class III          | Moderate public health or high personal risk | Prothrombin Time test strip/cartridge                      |
| High Risk | Class IV           | High public health risk                      | Molecular HCV, HIV cartridge or blood bank screening tests |

## HCV RNA Detection/Quantification (IU/ml)



# Development Of Training Resources

NPAAC TIER 4 DOCUMENT

## REQUIREMENTS FOR POINT OF CARE TESTING

(Second Edition 2021)

### 3. Training and competency

PoCT operators must be competent to perform PoCT in the local healthcare setting and be able to have confidence in the test result itself. Therefore, it is critical that staff have the necessary training and skills to perform such testing.



#### S3.1 PoCT must only be performed by operators who have undertaken relevant approved training and demonstrated that they are competent.

- C3.1(i) The organisation responsible for providing the PoCT service **must** have an approved training program.
- C3.1(ii) The training program **must** include but not be limited to the following areas:
  - (a) procedures for safely and competently performing patient tests and interpreting the validity of PoCT results
  - (b) education and training that covers common sources of error, including the source of pre- and post-analytical errors
  - (c) conducting quality control and quality assurance to regularly assess analytical quality of the PoCT device
  - (d) general awareness of privacy and confidentiality of patient information
  - (e) workplace health and safety as it relates to PoCT.
- C3.1(iii) Records of staff PoCT training, retraining and competency **must** be maintained.
- C3.1(iv) Competency **must** be reassessed after training at regular intervals and when new PoCT devices (different model or manufacturer) are deployed.
- C3.1(v) PoCT operators **must** receive training updates when a competency issue with that operator is identified or where the PoCT operator performs testing infrequently.

SOP  
Development




# Overview Of Operator Education and Training



### ASHM – Point-of-Care Testing

This online learning module consists of three modules and an assessment that should be completed in sequential order. The modules do not need to be completed in one sitting, you can come back to them at any time.

Select your module.



What is Hepatitis C (HCV)?



What is point-of-care testing?

# Study Design - Evaluation of operator training & quality

## Questionnaire topics:

Ensuring people at risk are screened  
 Interpreting results and diagnosing HCV  
 Collecting capillary samples  
 Performing HCV POCT  
 Operation and maintenance of GX

| Study Visit               | Screening (Enrolment) | ASHM Pre-requisite OLM | GeneXpert Theoretical Training | GeneXpert Practical Session | 6-month Post-training Review |
|---------------------------|-----------------------|------------------------|--------------------------------|-----------------------------|------------------------------|
| Questionnaire (Screening) | X                     |                        |                                |                             |                              |
| Questionnaire (Follow-up) |                       | X                      | X                              | X                           | X                            |
| Responses (n =)           | 98                    | 77                     | 55                             | 39                          | 4                            |


## Qualitative data analysis

Frequency of participant responses at each stage  
 Self-perceived competency assessed at each stage  
 5-part Likert scale then dichotomised  
 6-month post-training review in progress


## Quantitative data analysis

Data extraction from Program data base  
 QC and EQA participation and concordance  
 Valid tests and error rates

- 1 Not at all;
- 2 Have a slight knowledge, skills or confidence
- 3 Average competence amongst my peers
- 4 Confident and competent;
- 5 Very confident and competent



# Results – Workforce and Testing Volumes



## Data Extraction Overview

February 2022 to October 2022

Active sites = 31

HCV RNA tests = 3937

Patients tested = 3703



Operators (at any stage) = 104

# Results – Specimen Collection

How confident are you in your ability to draw a whole blood sample into a 100 $\mu$ L minivette?

Increasing linear trend in proportions of “confident and competent” across each training stage;  $P < 0.001$

Meaningful gain in “confident and competent” between post-GX Theory and post-GX Practical sessions (81% vs 92%);  $P = 0.22$







# Results – Specimen Collection, Errors and Experienced Operators

## Testing Errors

Unsuccessful tests = 8.8% (n= 348/3937)

- Poor quality samples (errors) = 82.2%
- Cartridge related issues (invalids) = 12.9%
- Device issues (no results) = 4.8%




# Results – Performing Tests


How confident are you in your understanding of the purpose of a quality control (QC, a known HCV positive and negative specimen) for HCV testing?

A significant increasing linear trend in proportions of “*confident and competent*” across each training stage;  $P < 0.001$

Note increase to 100% “*confident and competent*” in understanding the purposes of QC post-GX Practical session;  $P < 0.001$



■ <Average Confidence    ■ Confident & Competent



# Competency panel concordance

## Competency Panels (Quality Controls)

Two samples with known HCV results (Negative and Positive)

Operators must obtain expected results and viral load in target range

Manufactured by NRL

QC data August 2022 to February 2023

QC test episodes n = 563

**100% Concordance with expected results**




|     | ICPOCT Site Identifier | Initials | Date of Test | Specimen ID Name     | Cartridge Lot No. | QC Level | QC Lot No | Module | Qualitative Result | Viral Load (log10) | Qualitative Concordant | Quantitative Within Limits |
|-----|------------------------|----------|--------------|----------------------|-------------------|----------|-----------|--------|--------------------|--------------------|------------------------|----------------------------|
| 1   |                        |          |              |                      |                   |          |           |        |                    |                    |                        |                            |
| 324 | NSW1363                | JW       | 12/12/2022   | hcv-neg-dec-qe       | 14301             | Neg      | N221963   | 1      | NOT DETECTED       |                    | Concordant             |                            |
| 325 | NSW1363                | JW       | 12/12/2022   | hcv-pos-dec-qe       | 14301             | Pos      | N221963   | 2      | DETECTED           | 2.37               | Concordant             | Acceptable                 |
| 326 | NSW1363                | JW       | 12/12/2022   | hcv-neg-dec-ub       | 14301             | Neg      | N221963   | 4      | NOT DETECTED       |                    | Concordant             |                            |
| 327 | NSW1363                | JW       | 12/12/2022   | hcv-pos-dec-ub       | 14301             | Pos      | N221963   | 3      | DETECTED           | 2.58               | Concordant             | Acceptable                 |
| 328 | ACT1355                | JW       | 14/12/2022   | HCV POS DEC LK       | 14102             | Pos      | N221963   | 2      | DETECTED           | 2.53               | Concordant             | Acceptable                 |
| 329 | NSW1364                | JW       | 15/12/2022   | HCV-NEG-DEC-JV       | 14301             | Neg      | N221963   | 1      | NOT DETECTED       |                    | Concordant             |                            |
| 330 | NSW1364                | JW       | 15/12/2022   | HCV-pos-DEC-JV       | 14301             | Pos      | N221963   | 2      | DETECTED           | 2.1                | Concordant             | Acceptable                 |
| 331 | NSW1351                | JW       | 15/12/2022   | HCV-Neg-Dec          | 14301             | Neg      | N221963   | 4      | NOT DETECTED       |                    | Concordant             |                            |
| 332 | NSW1351                | JW       | 15/12/2022   | HCV-NEG-DEC          | 14301             | Neg      | N221963   | 4      | NOT DETECTED       |                    | Concordant             |                            |
| 333 | NSW 1340               | JW       | 19/12/2022   | HCV-POS-December     | 14102             | Pos      | N221963   | 4      | DETECTED           | 2.32               | Concordant             | Acceptable                 |
| 334 | NSW1363                | JW       | 19/12/2022   | HCV-Pos-Dec          | 14301             | Pos      | N221963   | 2      | DETECTED           | 2.44               | Concordant             | Acceptable                 |
| 335 | NSW1352                | JW       | 20/12/2022   | HCV-QC-POS-DEC22     | 14102             | Pos      | N221963   | 2      | DETECTED           | 2.39               | Concordant             | Acceptable                 |
| 336 | NSW1361                | JW       | 20/12/2022   | HCV-QC-POS-DEC       | 14102             | Pos      | N221963   | 2      | DETECTED           | 2                  | Concordant             | Acceptable                 |
| 337 | NSW1325                | JW       | 20/12/2022   | 94FA-0688-5F2F       | 14301             | Pos      | N221963   | 2      | DETECTED           | 2.61               | Concordant             | Acceptable                 |
| 338 | NSW1363                | JW       | 20/12/2022   | HCV_POS_DEC_PEJ      | 14301             | Pos      | N221963   | 2      | DETECTED           | 2.75               | Concordant             | Acceptable                 |
| 339 | NSW1358                | JW       | 20/12/2022   | hcv_pos_dec_bl       | 14301             | Pos      | N221963   | 2      | DETECTED           | 2.05               | Concordant             | Acceptable                 |
| 340 | NSW1371                | JW       | 21/12/2022   | HCV-QC-NEG-DEC       | 14301             | Neg      | N221963   | 4      | NOT DETECTED       |                    | Concordant             |                            |
| 341 | NSW1371                | JW       | 21/12/2022   | Xpert H 211222105840 | 14301             | Pos      | N221963   | 2      | DETECTED           | 2.32               | Concordant             | Acceptable                 |
| 342 | NSW1351                | JW       | 21/12/2022   | HCV-NEG-DEC-GR       | 14301             | Neg      | N221963   | 2      | NOT DETECTED       |                    | Concordant             |                            |
| 343 | NSW1351                | JW       | 21/12/2022   | HCV-POS-DEC-GR       | 14301             | Pos      | N221963   | 4      | DETECTED           | 2.12               | Concordant             | Acceptable                 |
| 344 | NSW1351                | JW       | 21/12/2022   | HCV-NEG-DEC-AV       | 14301             | Neg      | N221963   | 3      | NOT DETECTED       |                    | Concordant             |                            |
| 345 | NSW1351                | JW       | 21/12/2022   | HCV-POS-DEC-AV       | 14301             | Pos      | N221963   | 1      | DETECTED           | 2                  | Concordant             | Acceptable                 |
| 346 | SA1348                 | JW       | 21/12/2022   | HCV-QC POS DECEMBER  | 14102             | Pos      | N221963   | 3      | DETECTED           | 2                  | Concordant             | Acceptable                 |
| 347 | QLD1338                | JW       | 21/12/2022   | December 22 QC       | 14102             | Pos      | N221963   | 2      | DETECTED           | 2                  | Concordant             | Acceptable                 |
| 348 | NSW61214               | JW       | 21/12/2022   | HCV-Pos-Dec          | 14301             | Pos      | N221963   | 2      | DETECTED           | 2.35               | Concordant             | Acceptable                 |
| 349 | NSW1350                | JW       | 21/12/2022   | HCV-POS-DECEMBER     | 14102             | Pos      | N221963   | 2      | DETECTED           | 2                  | Concordant             | Acceptable                 |
| 350 | NSW1350                | JW       | 21/12/2022   | HCV-NEG-DEC-IC       | 14102             | Neg      | N221963   | 1      | NOT DETECTED       |                    | Concordant             |                            |
| 351 | NSW1350                | JW       | 21/12/2022   | HC-POS-DEC-IC        | 14102             | Pos      | N221963   | 2      | DETECTED           | 2.09               | Concordant             | Acceptable                 |
| 352 | SA1337                 | JW       | 21/12/2022   | 29C7-0689-B477       | 14301             | Pos      | N221963   | 2      | DETECTED           | 2.08               | Concordant             | Acceptable                 |
| 353 | NSW1351                | JW       | 22/12/2022   | HCV-POS-DEC-GR       | 14301             | Pos      | N223181   | 1      | DETECTED           | 2.47               | Concordant             | Acceptable                 |
| 354 | NSW1327                | JW       | 22/12/2022   | CP Dec 2022          | 13902             | Pos      | N221963   | 2      | DETECTED           | 2                  | Concordant             | Acceptable                 |
| 355 | QLD1344                | JW       | 23/12/2022   | HCV-DEC-POS          | 14301             | Pos      | N221963   | 2      | DETECTED           | 2.32               | Concordant             | Acceptable                 |
| 356 | NSW2377                | JW       | 23/12/2022   | B1FC-068C-63C4       | 14301             | Pos      | N221963   | 2      | DETECTED           | 2.16               | Concordant             | Acceptable                 |
| 357 | NSW 1340               | JW       | 9/01/2023    | HCV-QC-NEG-JAN 23    | 14102             | Neg      | N221963   | 3      | NOT DETECTED       |                    | Concordant             |                            |

# Results – Performing Tests on GeneXpert

How confident are you in your ability to perform an HCV Viral Load Fingerstick test on the GeneXpert platform?

A significant increasing linear trend in proportions of “*confident and competent*” across each training stage;  $P < 0.001$

Significant gain in “*confident and competent*” between post-GX Theory and post-GX Practical sessions (83% vs 97%);  $P < 0.001$



# Results – External Quality Assurance (EQA) October 2022

## External Quality Assurance (EQA) Program

Simulates patient samples with unknown HCV status

Five blinded samples (unknown HCV status)

Two challenges per year

Manufactured by NRL

October 2022

15/15 Sites

**100%** Participation Rate

One transcription error- initiated a retraining event



◆ Your Result.    ■ Testing sites whose result was consistent with the expected result.    ■ Testing sites whose result was inconsistent with the expected result.




# Results – Interpretation of HCV results

How confident are you in your ability to interpret the HCV viral load result from the GeneXpert platform?

A significant increasing linear trend in proportions of “*confident and competent*” across each training stage;  $P < 0.001$

Note significant increase to 100% “*confident and competent*” for post-GX Practical session;  $P < 0.001$

| Xpert® HCV VL test result               | Interpretation   | Action  |
|---|--|---|
| <b>HCV NOT DETECTED</b>                 | HCV RNA is not detected  | Follow local protocols for a non-detectable HCV RNA result.   |
| <b>HCV DETECTED &lt;100 IU/mL</b>       | HCV RNA is detected below the quantitative range of the assay. | Alert clinician to the presence of DETECTED HCV RNA at a level too low to be quantified by the GeneXpert.<br>Notify public health regarding DETECTED HCV RNA by GeneXpert method.<br>Arrange for venous sample to be collected for confirmatory HCV RNA testing at a referral laboratory.<br>The laboratory will notify jurisdictional public health notification of a confirmed positive result. |
| <b>HCV DETECTED XX IU/mL (log X.XX)</b> | HCV RNA is detected at XX IU/mL                                | Follow local and/or National protocols for DETECTABLE HCV RNA and jurisdictional mandatory notification.  |
| <b>HCV DETECTED &gt;1.00E08 IU/mL</b>   | HCV RNA is detected above the quantitative range of the assay. | Follow local and/or National protocols for DETECTABLE HCV RNA and jurisdictional mandatory notification.  |
| <b>INVALID</b>                          | Test was unsuccessful  | Repeat the test using a new minivette and new reagent cartridge.  |
| <b>ERROR</b>                            | Test was unsuccessful  | Repeat the test using a new minivette and new reagent cartridge.  |
| <b>NO RESULT</b>                        | Test was unsuccessful  | Repeat the test using a new minivette and new reagent cartridge.  |




# Results – EQA October 2022 – Sample C


## Sample C - External Quality Assurance (EQA)

Viral load at Limit of Detection (LoD) small proportion of “Not Detected” results expected

*Generates confusion around perceived discordances?*



◆ Your Result. ■ Testing sites whose result was consistent with the expected result. ■ Testing sites whose result was inconsistent with the expected result.



# Conclusions

Risk management of POCT services is imperative to ensure recognition and elimination of errors, that can jeopardise test results and patient safety.

## Standardised POC operator training

- Develops a greater understanding of quality management procedures
- Improves self-assessed GeneXpert competency
- Facilitates a high rate of valid tests on first attempt
- Unsuccessful tests are largely attributed poor quality samples





# Acknowledgements

Program managed by the Kirby Institute (PI: Prof. Jason Grebely & team) and  
Flinders University International Centre for Point-of-Care Testing (AI: Dr. Susan Matthews & team)

Funded by the Australian Government Department of Health

This operator training evaluation was funded by the RAPID CRE

## National HCV Operational Team

### Kirby Institute

- Jason Grebely
- David Silk
- Simon Comben
- Stephanie Davies
- Elise Tu
- Maria Martinez
- Jessie Payne
- Samira Hosseini-Hooshyar
- Rebecca Henry

### Flinders University

- Susan Matthews
- Mark Shephard
- Corey Markus
- Jae Williams
- Kirsty Emery
- Larissa Kahl

### St Vincent's Hospital

- Phillip Cunningham
- Mitchell Starr
- Beth Catlett

### Industry Partners

- Cepheid
- Gilead
- National Referral Laboratory
- Clinical Universe

# Acknowledgements




This program is funded by the Australian Government Department of Health

# Questions?





# Results –



# Results –

